23andMe, Genentech ask Avastin users to spit for science

08/8/2013 | Forbes

23andMe and Roche's Genentech unit are collaborating on an effort to identify genetic mutations that determine how patients respond to the cancer drug Avastin. The InVite Study asks patients who have taken Avastin for certain types of cancer to submit a saliva sample and possibly a blood sample, and answer questions in an online survey about their cancer and experience with Avastin. The study is part of a larger trend to involve patients and integrate technology in medicine, health care communications expert John Nosta writes.

View Full Article in:

Forbes

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA